PEG & ADCs
- Development of Current Four Generation ADCs And Next Generation ADCs
- The Rise of the TROP2-Directed ADCs for Solid Tumors
- ADC Drugs: Some Challenges To Be Solved
- ROR1 ADCs in Clinical Trials: MK-2140, NBE-002 & CS5001
- Cleavable Linkers Used In ADC Development
- Trophoblast Glycoprotein (TPGB/5T4): A New Target For ADC Drugs
- Summary of ADC Targets For Solid Tumors & Hematological Tumors
- Antibody-Drug Conjugates With Dual Payloads Against Heterogeneous Tumors
- Design Elements And Design Criteria For ADC Drugs
- Overview of ADC-Based Combination Therapies